Abcam, ab237750, Recombinant EBV gp340/220 Envelope Protein (Tagged)

Size: 100µg
Recombinant EBV gp340/220 Envelope Protein (Tagged) is a Epstein-Barr Virus (Strain B95-8) Fragment protein, in the 1 to 493 aa range, expressed in Escherichia coli, with >90%, suitable for SDS-PAGE, Mass Spec.
Key facts
Purity:>90% SDS-PAGE,
Expression system:Escherichia coli,
Tags:His tag N-Terminus,
Applications:Mass Spec, SDS-PAGESee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Biologically active:No,
Accession:P03200,
Animal free:No,
Carrier free:No,
Species:Epstein-Barr Virus (Strain B95-8),
Storage buffer:pH: 7.2 - 7.4Constituents: Tris buffer, 50% Glycerol (glycerin, glycerine)

Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The EBV gp340/220 Envelope Protein also known as the Epstein-Barr virus major glycoprotein gp350/220 plays an important role in the viral entry mechanism. It is approximately 340 kDa in mass and is expressed on the surface of the Epstein-Barr virus (EBV) particles. This glycoprotein mediates the attachment of virions to host cells by binding to the complement receptor type 2 (CR2/CD21) on B lymphocytes which facilitates the viral entry into the host cell. The expression of gp340/220 is restricted to EBV-infected cells and encapsulates the virus playing an integral role in its infectivity.
Biological function summary
This glycoprotein promotes viral entry by enhancing the fusion between the viral envelope and the host cell membrane. It is an important component of the viral entry machinery acting in conjunction with other viral proteins such as gp42 to initiate infection. It functions as part of a greater complex that mediates the initial stages of infection enabling the virus to establish itself in resting B cells and epithelial cells. By allowing the attachment and initial colonization of host cells EBV gp340/220 serves as an important facilitator of EBV's life cycle.
Pathways
EBV gp340/220 plays a substantial role in the viral infection process and influences pathways like the complement pathway and B cell activation pathway. It interacts prominently with CD21 a receptor on B cells to trigger the internalization of the virus. This interaction forms a basis for activating signaling pathways inside the host cell subsequently leading to events that promote viral replication and latent infection. Although gp350/220 remains distinct its functions influence other viral proteins such as LMP1 in downstream signaling pathways which contribute to virus persistence and oncogenesis.
EBV gp340/220 is closely linked to infectious mononucleosis and Burkitt's lymphoma. It initiates infection which may culminate in persistent latent infections contributing to the development of these conditions. In infectious mononucleosis this glycoprotein participates in binding to CR2/CD21 facilitating viral entry and causing the characteristic symptoms of the disease. In Burkitt’s lymphoma disturbances in pathways associated with EBV gp340/220 and LMP1 have been implicated in tumorigenesis illustrating the connection between the viral protein and disease progression.